Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

Brandon Kulengowski, Justin A. Clark, David S. Burgess

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

Original languageEnglish
Pages (from-to)372-375
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume93
Issue number4
DOIs
StatePublished - Apr 2019

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

Keywords

  • Amikacin
  • Carbapenem-resistant Enterobacteriaceae
  • Meropenem
  • Polymyxin B
  • Time kill

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin'. Together they form a unique fingerprint.

Cite this